Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis

Company Overview

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Key Stats

• Today's Range: $1.62 to $1.77
• 50-Day Range: $1.10 to $1.90
• 52-Week Range: $1.05 to $11.26
• Volume: 1.33 million shs
• Average Volume: 1.12 million shs
• Market Capitalization: $91.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.83
• Consensus Rating: Moderate Buy

Marinus Pharmaceuticals Stock Analysis - MarketRank™

Marinus Pharmaceuticals scored higher than 88% of companies evaluated by MarketBeat, and ranked 153rd out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Marinus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Marinus Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($1.88) to ($0.91) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Marinus Pharmaceuticals is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Marinus Pharmaceuticals is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Marinus Pharmaceuticals has a P/B Ratio of 5.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.28% of the outstanding shares of Marinus Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Marinus Pharmaceuticals has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Marinus Pharmaceuticals has recently increased by 5.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Marinus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Marinus Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.55

Percentage of Shares Shorted

5.28% of the outstanding shares of Marinus Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Marinus Pharmaceuticals has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Marinus Pharmaceuticals has recently increased by 5.84%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.61

News Sentiment

Marinus Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Marinus Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

Only 3 people have searched for MRNS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Marinus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -42% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Marinus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,433.00 in company stock.

Percentage Held by Insiders

Only 5.46% of the stock of Marinus Pharmaceuticals is held by insiders.

Percentage Held by Institutions

98.80% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MRNS Stock Analysis - Frequently Asked Questions

How have MRNS shares performed this year?

Marinus Pharmaceuticals' stock was trading at $10.87 on January 1st, 2024. Since then, MRNS shares have decreased by 84.6% and is now trading at $1.67.
View the best growth stocks for 2024 here.

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) posted its quarterly earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by $0.01. The biopharmaceutical company had revenue of $8.06 million for the quarter, compared to analyst estimates of $9.05 million. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 7,831.35% and a negative net margin of 493.14%.

When did Marinus Pharmaceuticals' stock split?

Shares of Marinus Pharmaceuticals reverse split before market open on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Marinus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Marinus Pharmaceuticals investors own include Nordic American Tankers (NAT), The Gabelli Dividend & Income Trust (GDV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Capricor Therapeutics (CAPR), Geron (GERN) and Realty Income (O).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 10/01/2024
• Next Earnings (Estimated): 11/05/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MRNS
• CUSIP: N/A
• CIK: 1267813
• Web: www.marinuspharma.com
• Phone: (484) 801-4670
• Fax: 203-315-0565
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.83
• High Stock Price Target: $13.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +388.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-141,400,000.00
• Net Margins: -493.14%
• Pretax Margin: -493.14%
• Return on Equity: -7,831.35%
• Return on Assets: -98.83%

Debt

• Debt-to-Equity Ratio: 5.68
• Current Ratio: 2.28
• Quick Ratio: 2.15

Sales & Book Value

• Annual Sales: $30.26 million
• Price / Sales: 3.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.31 per share
• Price / Book: 5.83

Miscellaneous

• Outstanding Shares: 54,934,000
• Free Float: 51,935,000
• Market Cap: $99.32 million
• Optionable: Optionable
• Beta: 1.13